novo nordisk oral semaglutide Here's Nordisk's First Obesity Drug In Europe With Proven Heart Health Impact Business | Novo Nordisk has

Nutrients 12 (3), 605

The danger isnt just hypothetical

The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite

If you have heart failure, it may get worse while you take thiazolidinediones (TZDs)

Figure 2 shows the distribution of the years of publication of the 50 studies in this review